Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
NCT02657512Phase 1Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Jan 2016
- Primary completion
- Feb 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of activated charcoal in Anticoagulant rodenticide poisoning (ARP) (3 arms), sponsored by CHU Saint-Etienne. Primary endpoint: Plasma concentrations of rivaroxaban at 24 hours. Started Jan 2016; status: completed.
02
Drugs
activated charcoal
03
Conditions
Anticoagulant rodenticide poisoning (ARP)
Beyond the preview
Go deeper on NCT02657512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657512.